Subscribe to Newsletter
Subspecialties Basic & Translational Research, Retina

Expanding Tunnel Vision

Scheie Eye Institute researchers have shown that a single intraocular injection of antisense oligonucleotide (ASO) sepofarsen can lead to marked changes at the fovea in Leber congenital amaurosis (LCA) patients with the common CEP290 mutation (1). In a clinical trial, 11 participants received an injection of the short RNA molecule (which increases CEP290 protein levels in the eye’s photoreceptors to improve retinal function). Ten of the participants were re-injected at intervals of three months. The current report is on the eleventh patient with reduced visual acuity, tunnel vision, and no night vision who received just a single dose. The researchers found substantial visual improvements, including expansion of the visual field, that were retained for more than 15 months.

Different measures allowed us to locate [...] improvements in the immediate foveal region.

“These improvements followed similar time courses [to the 10 other patients], peaking near three months post-injection, and many measures remained better than baseline at 15 months” explains Artur V. Cideciyan, Research Professor of Ophthalmology, and lead author of the study. “The extended durability was very surprising considering that sepofarsen half-life in the retina had been previously estimated to be around two months. Different measures allowed us to locate the distribution of the improvements in the immediate foveal region. However, further from here, improvements did not match predictions, suggesting that ASO access to photoreceptors in extrafoveal regions with thicker retina may be more limited.”

Why was the biological effect relatively slow to appear? Cideciyan hypothesised the delay could depend on diffusion and translocation of the ASO across the vitreous and retina into the foveal cone photoreceptor nucleus, and on synthesis of additional normal CEP290 mRNA and protein – “but it is likely that these steps occur in a matter of hours or days so they do not fully explain the ‘why’” he says. The team are now evaluating whether previously uninjected contralateral eyes demonstrate similar efficacy in an ongoing extension trial with nine of the original 11 study participants. They hope that, by better understanding the effect’s durability, they can establish an appropriate frequency for future maintenance injections.

Receive content, products, events as well as relevant industry updates from The Ophthalmologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. A Cideciyan et al., Nat Med [Online ahead of print]. PMID: 33795869.
About the Author
Phoebe Harkin

Associate Editor of The Ophthalmologist

I’ve always loved telling stories. So much so, I decided to make a job of it. I finished a Masters in Magazine Journalism and spent three years working as a creative copywriter before itchy feet sent me (back)packing. It took seven months and 13 countries, but I’m now happily settled on The Ophthalmologist, where I’m busy getting stuck into all things eyeballs.

Product Profiles

Access our product directory to see the latest products and services from our industry partners

Most Popular
Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine



The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: